Supernus Pharmaceuticals (Supernus Pharmaceuticals) EV-to-EBIT

Supernus Pharmaceuticals Annual Data
	Trend	Dec14	Dec15	Dec16	Dec17	Dec18	Dec19	Dec20	Dec21	Dec22	Dec23
EV-to-EBIT							7.51	6.87	16.98	28.29	264.34

Supernus Pharmaceuticals Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EV-to-EBIT																28.29	36.81	47.39	32.94	264.34

For the Drug Manufacturers - Specialty & Generic subindustry, Supernus Pharmaceuticals's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

For the Drug Manufacturers industry and Healthcare sector, Supernus Pharmaceuticals's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Supernus Pharmaceuticals's EV-to-EBIT falls into.

Supernus Pharmaceuticals EV-to-EBIT Calculation

Supernus Pharmaceuticals's EV-to-EBIT for today is calculated as:

Supernus Pharmaceuticals's current Enterprise Value is $1,367.4 Mil.
Supernus Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $5.2 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Supernus Pharmaceuticals  (NAS:SUPN) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Supernus Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Supernus Pharmaceuticals's Enterprise Value for the quarter that ended in Dec. 2023 was $1,370.3 Mil.
Supernus Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $5.2 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Supernus Pharmaceuticals EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Supernus Pharmaceuticals's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Supernus Pharmaceuticals (Supernus Pharmaceuticals) Business Description